Compare · BIIB vs TWST
BIIB vs TWST
Side-by-side comparison of Biogen Inc. (BIIB) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $27.94B, about 7.8x TWST ($3.58B).
- BIIB has been more active in the news (14 items in the past 4 weeks vs 8 for TWST).
- BIIB has more recent analyst coverage (25 ratings vs 12 for TWST).
- Company
- Biogen Inc.
- Twist Bioscience Corporation
- Price
- -
- -
- Market cap
- $27.94B
- $3.58B
- 1M return
- +3.29%
- -
- 1Y return
- +56.59%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 14
- 8
- Recent ratings
- 25
- 12
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest BIIB
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
- SEC Form 10-Q filed by Biogen Inc.
- Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Biogen Inc.
- SEC Form DEF 14A filed by Biogen Inc.
- FDA Approval for ZURZUVAE issued to BIOGEN INC
- Biogen upgraded by UBS with a new price target
- Biogen upgraded by Wells Fargo with a new price target
- TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
- Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Latest TWST
- Director Starovasnik Melissa A. sold $30,915 worth of shares (500 units at $61.83) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,222 units (SEC Form 4)
- President and COO Finn Patrick John sold $141,026 worth of shares (2,321 units at $60.76), decreasing direct ownership by 0.82% to 281,808 units (SEC Form 4) to cover withholding tax
- Chief Executive Officer Leproust Emily M. exercised 9,671 shares at a strike of $8.82 and sold $630,957 worth of shares (9,671 units at $65.24) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Laponis Adam
- Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
- SEC Form 4 filed by Laponis Adam
- SEC Form 4 filed by Laponis Adam
- SEC Form 144 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Starovasnik Melissa A.
- Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation